AR112166A1 - THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEPATITIS B - Google Patents

THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEPATITIS B

Info

Publication number
AR112166A1
AR112166A1 ARP180101692A ARP180101692A AR112166A1 AR 112166 A1 AR112166 A1 AR 112166A1 AR P180101692 A ARP180101692 A AR P180101692A AR P180101692 A ARP180101692 A AR P180101692A AR 112166 A1 AR112166 A1 AR 112166A1
Authority
AR
Argentina
Prior art keywords
sirna
seq
hepatitis
treatment
methods
Prior art date
Application number
ARP180101692A
Other languages
Spanish (es)
Original Assignee
Arbutus Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arbutus Biopharma Corp filed Critical Arbutus Biopharma Corp
Publication of AR112166A1 publication Critical patent/AR112166A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Un método para tratar la hepatitis B en un ser humano, que comprende administrarle al ser humano: 1) una formulación de nanopartículas lipídicas que comprende ARNip 1 (SEQ ID Nº 1 y 2), ARNip 2 (SEQ ID Nº 3 y 4) y ARNip 3 (SEQ ID Nº 5 y 6) y 2) un interferón (IFN). Reivindicación 45: Una composición que comprende: (a) una formulación de nanopartículas lipídicas que comprende ARNip 1 (SEQ ID Nº 1 y 2), ARNip 2 y (SEQ ID Nº 3 y 4) y ARNip 3 (SEQ ID Nº 5 y 6) y (b) un interferón.Claim 1: A method for treating hepatitis B in a human being, which comprises administering to the human being: 1) a lipid nanoparticle formulation comprising siRNA 1 (SEQ ID No. 1 and 2), siRNA 2 (SEQ ID No. 3 and 4) and siRNA 3 (SEQ ID Nos 5 and 6) and 2) an interferon (IFN). Claim 45: A composition comprising: (a) a lipid nanoparticle formulation comprising siRNA 1 (SEQ ID Nos. 1 and 2), siRNA 2 and (SEQ ID Nos. 3 and 4) and siRNA 3 (SEQ ID Nos. 5 and 6 ) and (b) an interferon.

ARP180101692A 2017-06-16 2018-06-15 THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEPATITIS B AR112166A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762520981P 2017-06-16 2017-06-16

Publications (1)

Publication Number Publication Date
AR112166A1 true AR112166A1 (en) 2019-09-25

Family

ID=64660917

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180101692A AR112166A1 (en) 2017-06-16 2018-06-15 THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEPATITIS B

Country Status (3)

Country Link
AR (1) AR112166A1 (en)
TW (1) TW201919653A (en)
WO (1) WO2018232330A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200003390A (en) 2017-05-08 2020-01-09 그릿스톤 온콜로지, 인코포레이티드 Alpha virus neoantigen vector
SG11202113187WA (en) 2019-05-30 2021-12-30 Gritstone Bio Inc Modified adenoviruses
JP2022540699A (en) * 2019-07-18 2022-09-16 ウエヌイグレックオ・ファーマ How to reduce the adverse effects of interferon
WO2021236389A2 (en) * 2020-05-16 2021-11-25 Bond Jason R Treatment of known and unknown viral infection with lipid agents
IL300026A (en) 2020-08-06 2023-03-01 Gritstone Bio Inc Multiepitope vaccine cassettes
WO2024214041A1 (en) * 2023-04-12 2024-10-17 Glaxosmithkline Intellectual Property Development Limited Methods of treating chronic hepatitis b

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067249B2 (en) * 2003-05-19 2006-06-27 The University Of Hong Kong Inhibition of hepatitis B virus (HBV) replication by RNA interference
WO2006096018A1 (en) * 2005-03-09 2006-09-14 Mogam Biotechnology Research Institute Small interfering rna and pharmaceutical composition for treatment of hepatitis b comprising the same
JP2009504706A (en) * 2005-08-15 2009-02-05 エフ．ホフマン−ラ ロシュ アーゲー PEG-IFNα and ribavirin for HBV treatment
US9006417B2 (en) * 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
RU2017114964A (en) * 2014-10-02 2018-11-07 Протива Байотерапьютикс, Инк. COMPOSITIONS AND METHODS FOR SUPPRESSING EXPRESSION OF THE HEPATITIS B VIRUS GENE

Also Published As

Publication number Publication date
WO2018232330A1 (en) 2018-12-20
TW201919653A (en) 2019-06-01

Similar Documents

Publication Publication Date Title
AR112166A1 (en) THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEPATITIS B
MX2018014573A (en) Zika virus vaccine.
MX2019011215A (en) Nucleic acids encoding crispr-associated proteins and uses thereof.
MX2022010270A (en) A novel approach for treatment of cancer using immunomodulation.
WO2018115527A3 (en) Mers coronavirus vaccine
CL2019000732A1 (en) Huntington's disease avv treatment.
TR201900649T4 (en) Mrna therapy for the treatment of ocular diseases.
PH12018502634A1 (en) Topical compositions of apremilast
AR106582A1 (en) SUBCUTANEOUS FORMULATIONS OF ANTI-CD38 ANTIBODIES AND THEIR USES
NZ742018A (en) Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect
BR112016024352A2 (en) "recombinant listeria strain, recombinant listeria, pharmaceutical composition, and methods of inducing an immune response against a tumor or cancer in a human and listeria individual"
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
MX2016012799A (en) Methods for treating hcv.
MX2018004616A (en) Cosmetic composition having probiotic bacteria.
EA201890507A1 (en) COMBINATION OF ANTI-VIRAL DIRECT ACTION AND RIBAVIRIN FOR THE TREATMENT OF PATIENTS WITH HCV
PH12020550821A1 (en) Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration
MX2018010223A (en) Combination therapy for treatment of ovarian cancer.
MX2020004716A (en) Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody.
PE20181332A1 (en) METHODS OF SEDATION AND PARENTERAL FORMULATION FOR USE DURING THE TREATMENT OF CRITICAL CARE
MX2018000240A (en) Methods for treating hcv.
AR093908A1 (en) FUSION OF HUMAN AND ALBUMINE GROWTH HORMONE, FORMULATION AND USES OF THE SAME
ECSP20055797A (en) METHODS AND COMPOSITIONS TO TREAT CHRONIC PULMONARY DISEASES
ZA202002107B (en) Use of specific sirna against protein s for the treatment of hemophilia
MX2016012722A (en) Methods for treating hcv.
CL2020000508A1 (en) Anti-egfr drug-antibody (adc) conjugates and their uses.

Legal Events

Date Code Title Description
FB Suspension of granting procedure